Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679926 · ClinicalTrials.gov registry record · Phase 4
Kaletra and Viread in Antiretroviral Naïve Patients
A Phase 4 study, sponsored by Oklahoma State University Center for Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00679926: Clinical Trial Phase 4 study, sponsored by Oklahoma State University Center for Health Sciences.
NCT00679926 is a Phase 4 study that was terminated before completion, run by Oklahoma State University Center for Health Sciences. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679926, a Phase 4 study, was terminated before completion, sponsored by Oklahoma State University Center for Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.
Primary Outcome
To assess the efficacy of once daily antiretroviral therapy with Viread 300mg and Kaletra 800mg/200mg in suppressing HIV RNA levels to \<50 copies/ml in antiretroviral naïve patients. This will be done by the proportion of patients with plasma HIV-1 RNA levels M 50 copies/ml at the end of 48 weeks of therapy.
Interventions
- DRUG Once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Why NCT00679926 stopped before completion
NCT00679926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Once daily is the first listed.
NCT00679926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00679926 about?
NCT00679926 is a clinical study titled "Kaletra and Viread in Antiretroviral Naïve Patients". Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.
What is the current status of trial NCT00679926?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00679926?
The interventions under investigation include: Once daily (DRUG).
Who is sponsoring clinical trial NCT00679926?
This trial is sponsored by Oklahoma State University Center for Health Sciences, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00679926's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia